Reuters logo
10 天前
BRIEF-Novartis confirms 5 year data for first, only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy, safety profile in psoriasis
2017年7月14日 / 晚上8点08分 / 10 天前

BRIEF-Novartis confirms 5 year data for first, only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy, safety profile in psoriasis

1 分钟阅读

July 14 (Reuters) - Novartis AG:

* Novartis confirms 5 year data for first and only fully-human il-17a inhibitor cosentyx® reinforcing sustained efficacy and safety profile in psoriasis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below